DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|rareLife solutions 606 Post Road East #397
Westport, CT 06880
|You are receiving this because you have an account on www.oneAMYLOIDOSISvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
Alnylam Presents New 18-Month Results From Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced new positive results from an 18-month analysis of exploratory cardiac endpoints in the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis. The 18-month findings show that in a pre-defined cardiac subpopulation, treatment with vutrisiran was associated with improvements in exploratory cardiac endpoints relative to external placebo, including levels of NT-proBNP, a measure of cardiac stress, and a trend towards improvement in echocardiographic parameters.
Consistent beneficial effects on cardiac measures were observed in the modified intent-to-treat (mITT) group. Additionally, in a planned cohort of patients from the mITT population, vutrisiran treatment reduced cardiac uptake of technetium on scintigraphy imaging relative to baseline in a majority of assessable patients, including those with Perugini grade >=2 at baseline, suggesting that patients with the highest degrees of cardiac amyloid burden may recognize benefit from a TTR silencer.
videos & visualsSteroids, IMiDs, and Alkylators in Amyoidosis: Dr. Larry Anderson – ASG Webinar 2/13https://www.youtube.com/watch?v=NrEjyVeJ...
educationEvolutive Echocardiographic Changes in Cardiac Amyloidosis: Look at the Whole PictureDoppler echocardiogram provides not only...
people & placesKeyur B. Shah, MDDr. Keyur Shah is a Chief of the Section...
people & placesTaxiarchis Kourelis, MDDr. Taxiarchis Kourelis is a hematology ...
videos & visualsIntellia CRISPR CAS9 Update – ASG Webinar 11/11https://www.youtube.com/watch?v=K2TmwAfu...
educationLocalised Nasopharyngeal Amyloidosis: The Importance of Postoperative Follow-upLocalised nasopharyngeal amyloidosis is ...
people & placesRafat Abonour, MDRafat Abonour is a Professor in the Depa...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.